Ligny; Yannick Aime Eddy

Patent Applications and Registrations

Patent applications and USPTO patent grants for Ligny; Yannick Aime Eddy.The latest application filed is for "cyanoindoline derivatives as nik inhibitors".

Company Profile

3.15.13

Ligny; Yannick Aime Eddy - Issy-les Moulineaux FR
Ligny; Yannick Aime Eddy - Issy-les Moulineaux Cedex 9 FR
Ligny; Yannick Aime Eddy - Sotteville-les-Rouen FR
Ligny; Yannick Aime Eddy - Val de Reuil FR

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Cyanoindoline derivatives as NIK inhibitors Grant 11,186,589 - Stansfield , et al. November 30, 2	2021-11-30
Heteroaromatic derivatives as NIK inhibitors Grant 11,136,311 - Stansfield , et al. October 5, 2	2021-10-05
Cyanoindoline Derivatives As Nik Inhibitors App 20210032267 - Stansfield; Ian ; et al.	2021-02-04
Heteroaromatic Derivatives As Nik Inhibitors App 20190359598 - Stansfield; Ian ; et al.	2019-11-28
Cyanoindoline Derivatives As Nik Inhibitors App 20190119299 - Stansfield; Ian ; et al.	2019-04-25
Substituted quinoxalines as FGFR kinase inhibitors Grant 9,856,236 - Saxty , et al. January 2, 2	2018-01-02
N-(2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-5-yl)-4-quinazolinamine and N-(2,3-dihydro-1H-indol-5-yl)-4-quinazolinamine derivatives as perk inhibitors Grant 9,688,662 - Stansfield , et al. June 27, 2	2017-06-27
Substituted quinoxalines as FGFR kinase inhibitors Grant 9,290,478 - Saxty , et al. March 22, 2	2016-03-22
NOVEL N-(2,3-DIHYDRO-1H-PYRROLO[2,3-b]PYRIDIN-5-YL)-4-QUINAZOLINAMINE AND N-(2,3-DIHYDRO-1H-INDOL-5-YL)-4-QUINAZOLINAMINE DERIVATIVES AS PERK INHIBITORS App 20160039798 - Stansfield; Ian ; et al.	2016-02-11
Substituted Quinoxalines As Fgfr Kinase Inhibitors App 20160031856 - SAXTY; Gordon ; et al.	2016-02-04
Imidazo [1,2-A]pyridine derivatives as FGFR kinase inhibitors for use in therapy Grant 8,722,687 - Saxty , et al. May 13, 2	2014-05-13
Substituted Benzopyrazin Derivatives As Fgfr Kinase Inhibitors For The Treatment Of Cancer Diseases App 20130267525 - Saxty; Gordon ; et al.	2013-10-10
Inhibitors of the interaction between MDM2 and P53 Grant 8,404,683 - Lacrampe , et al. March 26, 2	2013-03-26
Imidazo [1,2-a]pyridine Derivatives As Fgfr Kinase Inhibitors For Use In Therapy App 20120041000 - Saxty; Gordon ; et al.	2012-02-16
Substituted pyrazolo[3,4-D]pyrimidines as cell cycle kinase inhibitors Grant 7,947,694 - Freyne , et al. May 24, 2	2011-05-24
5-membered annelated heterocyclic pyrimidines as kinase inhibitors Grant 7,947,695 - Freyne , et al. May 24, 2	2011-05-24
Inhibitors of the Interaction Between MDM2 and P53 App 20110053937 - Lacrampe; Jean Fernand Armand ; et al.	2011-03-03
Inhibitors of the interaction between MDM2 and p53 Grant 7,834,016 - Lacrampe , et al. November 16, 2	2010-11-16
5-Membered Annelated Heterocyclic Pyrimidines As Kinase Inhibitors App 20080070914 - Freyne; Eddy Jean Edgard ; et al.	2008-03-20
Inhibitors of the Interaction Between Mdm2 and P53 App 20080039472 - Lacrampe; Jean Fernand Armand ; et al.	2008-02-14
Pyrazolopyrimidines as Cell Cycle Kinase Inhibitors App 20080039477 - Freyne; Eddy Jean Edgard ; et al.	2008-02-14
Intermediate compounds in the preparation of farnnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N-or C linked imidazoles Grant 6,444,812 - Venet , et al. September 3, 2	2002-09-03
Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles App 20020049327 - Venet, Marc Gaston ; et al.	2002-04-25
Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles Grant 6,187,786 - Venet , et al. February 13, 2	2001-02-13

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.